| Allentown Associates In Psychiatry | |
|
401 N 17th St Suite 304 Allentown PA 18104-5014 | |
| (610) 820-3900 | |
| (610) 820-3835 |
| Full Name | Allentown Associates In Psychiatry |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 401 N 17th St, Allentown, Pennsylvania |
| Authorized Official Name and Position | Paul K Gross (PROPRIETOR) |
| Authorized Official Contact | 6108203900 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Allentown Associates In Psychiatry 401 N 17th St Suite 304 Allentown PA 18104-5014 Ph: (610) 820-3900 | Allentown Associates In Psychiatry 401 N 17th St Suite 304 Allentown PA 18104-5014 Ph: (610) 820-3900 |
| NPI Number | 1528163938 |
|---|---|
| Provider Enumeration Date | 09/13/2006 |
| Last Update Date | 08/22/2020 |
| Medicare PECOS PAC ID | 0244226421 |
|---|---|
| Medicare Enrollment ID | O20040422001232 |
News Archive
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
The scientists observed that a protein called P-glycoprotein (P-gp), which causes resistance to chemotherapy in many tumor types, is able to physically "jump" or transfer between tumor cells and retain its functional properties, protecting otherwise sensitive cells from the effects of anti-cancer treatment in vivo and in vitro.
In those split seconds when people witness others in distress, neural pathways in the brain support the drive to help through facets of imagination that allow people to see the episode as it unfolds and envision how to aid those in need, according to a team of Boston College researchers.
MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.
The roundworm C. elegans, a staple of laboratory research, may be key in unlocking one of the central biological mysteries: why we sleep.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528163938 | NPI | - | NPPES |
| 0018813750005 | Medicaid | PA | |
| 511482 | Other | PA | HIGHMARK BLUE SHIELD |
| 02345500 | Other | PA | CAPITAL BLUE CROSS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | (* (Not Available)) | Primary |
| Provider Name | Paul K Gross |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1598871097 PECOS PAC ID: 8123082955 Enrollment ID: I20050316000220 |
News Archive
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
The scientists observed that a protein called P-glycoprotein (P-gp), which causes resistance to chemotherapy in many tumor types, is able to physically "jump" or transfer between tumor cells and retain its functional properties, protecting otherwise sensitive cells from the effects of anti-cancer treatment in vivo and in vitro.
In those split seconds when people witness others in distress, neural pathways in the brain support the drive to help through facets of imagination that allow people to see the episode as it unfolds and envision how to aid those in need, according to a team of Boston College researchers.
MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.
The roundworm C. elegans, a staple of laboratory research, may be key in unlocking one of the central biological mysteries: why we sleep.
› Verified 8 days ago
| Provider Name | Gregory K Palmer |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1154437663 PECOS PAC ID: 5395924674 Enrollment ID: I20110119001215 |
News Archive
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
The scientists observed that a protein called P-glycoprotein (P-gp), which causes resistance to chemotherapy in many tumor types, is able to physically "jump" or transfer between tumor cells and retain its functional properties, protecting otherwise sensitive cells from the effects of anti-cancer treatment in vivo and in vitro.
In those split seconds when people witness others in distress, neural pathways in the brain support the drive to help through facets of imagination that allow people to see the episode as it unfolds and envision how to aid those in need, according to a team of Boston College researchers.
MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.
The roundworm C. elegans, a staple of laboratory research, may be key in unlocking one of the central biological mysteries: why we sleep.
› Verified 8 days ago
News Archive
Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
The scientists observed that a protein called P-glycoprotein (P-gp), which causes resistance to chemotherapy in many tumor types, is able to physically "jump" or transfer between tumor cells and retain its functional properties, protecting otherwise sensitive cells from the effects of anti-cancer treatment in vivo and in vitro.
In those split seconds when people witness others in distress, neural pathways in the brain support the drive to help through facets of imagination that allow people to see the episode as it unfolds and envision how to aid those in need, according to a team of Boston College researchers.
MorphoSys AG and US-based Xencor, Inc. today announced the successful completion of patient enrollment in the phase 1 clinical trial evaluating MOR208.
The roundworm C. elegans, a staple of laboratory research, may be key in unlocking one of the central biological mysteries: why we sleep.
› Verified 8 days ago
Lvpg Neuropsychology - 1250 Cedar Crest Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1250 S Cedar Crest Blvd, Suite 410, Allentown, PA 18103 Phone: 610-402-3500 | |
Catholic Charities, Allentown Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 402 Chew St, Allentown, PA 18102 Phone: 610-435-1541 | |
Ida Andrea Olmeda Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1700 Hanover Ave, Allentown, PA 18109 Phone: 484-357-7599 Fax: 610-439-8004 | |
Bayada Home Health Care, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 961 Marcon Blvd Ste 103, Allentown, PA 18109 Phone: 484-795-5920 Fax: 484-795-5921 | |
Jewish Family Service Of The Lehigh Valley Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 2004 W Allen St, Allentown, PA 18104 Phone: 610-821-8722 | |
Vitalistic Therapeutic Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1406 W Hamilton St, Allentown, PA 18102 Phone: 610-433-4383 | |
Alicia Coffman Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1011 Brookside Rd Ste 302, Allentown, PA 18106 Phone: 484-809-9366 |